|
|
|
|
Dyadic CEO Discusses how his Company Could Expedite Vaccine Production
(Note: companies that
could be impacted by the content of this article are listed at the base of the
story [desktop version]. This article uses third-party references to provide a
bullish, bearish, and balanced point of view; sources are listed after the
Balanced section.)
In an interview, Dyadic CEO Mark Emalfarb told Trish Regan of FOX Business News that his company has the technology to allow them to mass-produce a vaccine should one get approved. “We developed the technology platform that we’ve been developing for years over two and half decades to make proteins at large scale, at very low cost,” Emalfarb said. Watch
Video